Trial Profile

A Phase 1/2 study to evaluate safety, pharmacokinetics, biological activity, and exploratory biomarkers for frontotemporal lobar degeneration (FTLD).

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CC 001 (Primary)
Indications Frontotemporal dementia
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

29 Dec 2025 New trial record
08 Dec 2025 According to a Glyconex media release, the company has entered into a CDMO service agreement with the Institute of Science Tokyo (Science Tokyo) and Change Cure Co., under which Glyconex will provide GMP grade drug substance manufacturing and regulatory support to enable initiation of a Phase 1/2a clinical trial in Japan of CC001. Change Cure holds exclusive worldwide rights for development and commercialization, and is responsible for advancing CC001 through clinical evaluation.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com